Exploring NYSE:HAE's quality characteristics.

In this article we will dive into HAEMONETICS CORP/MASS (NYSE:HAE) as a possible candidate for quality investing. Investors should always do their own research, but we noticed HAEMONETICS CORP/MASS showing up in our Caviar Cruise quality screen, which makes it worth to investigate a bit more.

Some of the quality metrics of NYSE:HAE highlighted

• Over the past 5 years, HAEMONETICS CORP/MASS has experienced impressive revenue growth, with 5.27% increase. This demonstrates the company's ability to effectively expand its top line and suggests a positive outlook for future revenue generation.
• The ROIC excluding cash and goodwill of HAEMONETICS CORP/MASS stands at 21.03%, reflecting the company's strong financial management and profitability. This metric underscores its ability to generate favorable returns on the capital invested in its core operations.
• HAEMONETICS CORP/MASS maintains a healthy Debt/Free Cash Flow Ratio of 4.35, indicating a strong financial position and prudent debt management. This ratio suggests the company has sufficient free cash flow to cover its debt obligations and highlights its ability to generate cash from operations.
• HAEMONETICS CORP/MASS demonstrates consistent Profit Quality over the past 5 years, with a strong 124.0%. This indicates the company's ability to generate sustainable and reliable profits, showcasing its long-term profitability and financial stability.
• With a robust 5-year EBIT growth of 12.23%, HAEMONETICS CORP/MASS showcases its ability to consistently expand its operating profitability. This trend indicates the company's effective cost management and revenue generation strategies.
• With EBIT 5-year growth outpacing its Revenue 5-year growth, HAEMONETICS CORP/MASS showcases its effective cost management and enhanced operational performance. This suggests the company's ability to generate higher earnings from its revenue streams.

Zooming in on the fundamentals.

ChartMill assigns a Fundamental Rating to every stock. This score, ranging from 0 to 10, is updated daily and is determined by evaluating multiple fundamental indicators and properties.

Overall HAE gets a fundamental rating of 7 out of 10. We evaluated HAE against 205 industry peers in the Health Care Equipment & Supplies industry. HAE has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. HAE is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, HAE could be worth investigating further for growth and quality investing!.

Our latest full fundamental report of HAE contains the most current fundamental analsysis.

More ideas for quality investing can be found on ChartMill in our Caviar Cruise screen.

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.